Allergen immunotherapy for allergic asthma: The future seems bright

Zuzana Diamant*, Maurits van Maaren, Antonella Muraro, Milos Jesenak, Ilja Striz*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)

Abstract

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.

Original languageEnglish
Article number107125
JournalRespiratory Medicine
Volume210
DOIs
Publication statusPublished - Apr 2023

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Allergen immunotherapy for allergic asthma: The future seems bright'. Together they form a unique fingerprint.

Cite this